Roivant Sciences (NASDAQ:ROIV) CEO Sells 200,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $21.92, for a total transaction of $4,384,000.00. Following the completion of the sale, the chief executive officer directly owned 1,654,597 shares of the company’s stock, valued at approximately $36,268,766.24. This trade represents a 10.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The stock was sold at an average price of $22.53, for a total value of $1,689,750.00.
• On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.45, for a total value of $4,490,000.00.
• On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.85, for a total transaction of $4,170,000.00.
• On Friday, November 7th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.22, for a total transaction of $4,044,000.00.
• On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The stock was sold at an average price of $17.06, for a total transaction of $2,020,211.08.
• On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The stock was sold at an average price of $17.05, for a total transaction of $5,426,708.10.

Roivant Sciences Trading Up 1.6%

Shares of ROIV stock traded up $0.37 during trading hours on Wednesday, hitting $23.81. The company had a trading volume of 5,806,136 shares, compared to its average volume of 6,468,146. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $23.83. The firm’s fifty day moving average is $21.40 and its 200 day moving average is $16.46.

Institutional Trading of Roivant Sciences

A number of hedge funds have recently modified their holdings of ROIV. Jones Financial Companies Lllp increased its position in Roivant Sciences by 226.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after purchasing an additional 1,148 shares during the period. Allworth Financial LP grew its stake in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the period. Bessemer Group Inc. increased its stake in Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares in the last quarter. CWM LLC raised its holdings in shares of Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after acquiring an additional 920 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd raised its position in Roivant Sciences by 75.8% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock valued at $67,000 after buying an additional 1,900 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on ROIV shares. Jefferies Financial Group raised their price objective on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. Guggenheim reiterated a “buy” rating and issued a $28.00 price objective on shares of Roivant Sciences in a research report on Thursday, December 18th. Weiss Ratings raised Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. HC Wainwright increased their target price on Roivant Sciences from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a report on Sunday, November 16th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.19.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.